Do you switch from Eliquis to Pradaxa in patients who experience a recurrent ischemic stroke while on Eliquis, considering their different mechanisms of action?

I tend not to switch patients from Eliquis/apixaban to Pradaxa/dabigratan. There is no good data to support this and while the mechanistic argument may make sense, especially since dabigatran, a direct thrombin inhibitor, was the only DOAC to reduce ischemic stroke events in a statistically signific...

If a person taking apixaban (Eliquis) for atrial fibrillation has an ischemic stroke, one may consider this a "breakthrough" stroke, or stroke despite anticoagulation, assuming that the adherence is good on correct dosing without competing mechanisms.

So far, the data are not encouraging for switchin...

I usually don't switch, as there is evidence that making a switch is better for secondary stroke prevention.